Opadotin | antitubulin cytotoxic drug-linker | CAS#1415246-35-3

MedKoo Cat#: 124902 | Name: Opadotin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Opadotin is a potent antitubulin cytotoxic drug-linker.

Chemical Structure

Opadotin

CAS#1415246-35-3 (free base)

Theoretical Analysis

MedKoo Cat#: 124902

Name: Opadotin

CAS#: 1415246-35-3 (free base)

Chemical Formula: C47H82N6O12

Exact Mass: 922.6000

Molecular Weight: 923.20

Elemental Analysis: C, 61.15; H, 8.95; N, 9.10; O, 20.80

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

2364345-05-9 (bis) 1415246-35-3 (free base)

Synonym

PEG4-aminooxy-MMAF; 1415246-35-3; Opadotin; AMBERSTATIN; OPADOTIN [USAN]; D5J6JHG50S; SCHEMBL14234037; AS269; AS-269

IUPAC/Chemical Name

((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-14-(aminooxy)-2-isopropyl-3-methyl-6,9,12-trioxa-3-azatetradecanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanoyl)-L-phenylalanine

InChi Key

OJYZGXVPCDZLCK-KVEFUIBJSA-N

InChi Code

InChI=1S/C47H82N6O12/c1-12-33(6)42(52(9)46(57)40(31(2)3)50-45(56)41(32(4)5)51(8)21-22-62-23-24-63-25-26-64-27-28-65-48)38(60-10)30-39(54)53-20-16-19-37(53)43(61-11)34(7)44(55)49-36(47(58)59)29-35-17-14-13-15-18-35/h13-15,17-18,31-34,36-38,40-43H,12,16,19-30,48H2,1-11H3,(H,49,55)(H,50,56)(H,58,59)/t33-,34+,36-,37-,38+,40-,41-,42-,43+/m0/s1

SMILES Code

[H][C@]([C@@H](C)CC)([C@@H](CC(=O)N1CCC[C@@]1([H])[C@H](OC)[C@@H](C)C(=O)N[C@@H](CC2=CC=CC=C2)C(O)=O)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)CCOCCOCCOCCON)C(C)C

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 923.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Skidmore L, Sakamuri S, Knudsen NA, Hewet AG, Milutinovic S, Barkho W, Biroc SL, Kirtley J, Marsden R, Storey K, Lopez I, Yu W, Fang SY, Yao S, Gu Y, Tian F. ARX788, a Site-specific Anti-HER2 Antibody-Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1-resistant Breast and Gastric Cancers. Mol Cancer Ther. 2020 Sep;19(9):1833-1843. doi: 10.1158/1535-7163.MCT-19-1004. Epub 2020 Jul 15. PMID: 32669315. 2: Zhang Y, Qiu MZ, Wang JF, Zhang YQ, Shen A, Yuan XL, Zhang T, Wei XL, Zhao HY, Wang DS, Zhao Q, Xiong GZ, Ji YP, Liang XJ, Xia G, Xu RH. Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma. Cell Rep Med. 2022 Nov 15;3(11):100814. doi: 10.1016/j.xcrm.2022.100814. PMID: 36384091; PMCID: PMC9729820. 3: Nagaraja Shastri P, Zhu J, Skidmore L, Liang X, Ji Y, Gu Y, Tian F, Yao S, Xia G. Nonclinical Development of Next-generation Site-specific HER2-targeting Antibody-drug Conjugate (ARX788) for Breast Cancer Treatment. Mol Cancer Ther. 2020 Sep;19(9):1822-1832. doi: 10.1158/1535-7163.MCT-19-0692. Epub 2020 Jun 4. PMID: 32499302. 4: Ayyamperumal S, Dj D, Tallapaneni V, Mohan S, S B, Selvaraj J, Joghee NM, Mjn C. Molecular docking analysis of α-Topoisomerase II with δ-Carboline derivatives as potential anticancer agents. Bioinformation. 2021 Jan 31;17(1):249-265. doi: 10.6026/97320630017249. PMID: 34393444; PMCID: PMC8340707. 5: Liang XJ, Gong LY, Zhou F, Zhou DM, Zhu JJ. [Pharmacological effects of site specific conjugated anti-human epidermal growth factor receptor 2-antibody drug conjugate using unnatural amino acid technology]. Beijing Da Xue Xue Bao Yi Xue Ban. 2019 Oct 18;51(5):797-804. Chinese. doi: 10.19723/j.issn.1671-167X.2019.05.002. PMID: 31624380; PMCID: PMC7433521.